Out of pocket getting out of hand - reducing the financial toxicity of rapidly approved drugs

New England Journal of Medicine

15 February 2025 - In 2023, Teresa was diagnosed with amyotrophic lateral sclerosis. Several months later, her family started a GoFundMe campaign to raise money for an all terrain wheelchair so Teresa could continue traversing hiking trails near her home.

They also faced bills of $4,000/month to cover copayments for sodium phenylbutyrate–taurursodiol (Relyvrio), a drug that was approved by the FDA.

Read New England Journal of Medicine Perspective

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Regulation , Pricing